IP Library › Granted Patent US 8,048,882
Granted Patent B2
US 8,048,882 · App. 10/584,661 · Granted Nov 1, 2011

Pharmaceutical compositions with increased activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,882
App. No.
10/584,661
Granted
Nov 1, 2011
Kind
B2
Abstract

The invention relates to novel pharmaceutical combinations with improved sodium channel blocking effect. Further, the invention relates to the use of said pharmaceutical combinations in chronic pain, in disturbances of the motor system, in epilepsy, as well as in other therapeutic fields where the use of sodium channel blockers is acceptable.

Claims (10)

1. A pharmaceutical composition comprising a sodium channel blocker selected from the group consisting of lamotrigine and crobenetine, in combination with a selective serotonin uptake inhibitor selected from the group consisting of fluoxetine, paroxetine, sertraline, escitalopram and citalopram, wherein said composition has a potentiating effect.

2. A pharmaceutical composition according to claim 1 , wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.

3. A pharmaceutical composition according to claim 1 , wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.

4. A pharmaceutical composition according to claim 1 , wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.

5. A pharmaceutical composition according to claim 1 , wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.

6. A method for the treatment of chronic pain or epilepsy in a mammal comprising administering to a mammal in need of the treatment a therapeutically effective amount of pharmaceutical composition comprising a sodium channel blocker selected from the group consisting of lamotrigine and crobenetine, and a selective serotonin uptake inhibitor selected from the group consisting of fluoxetine, paroxetine, sertraline, escitalopram and citalopram, wherein said treatment has a potentiating effect.

7. A method according to claim 6 , wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.

8. A method according to claim 6 , wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.

9. A method according to claim 6 , wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.

10. A method according to claim 6 , wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.

Assignments (3)
CHANGE OF NAME Recorded Sep 20, 2011
From: RICHTER GEDEON VEGYESZETI GYAR RT.
To: RICHTER GODEON NYRT.
Reel/Frame 026954/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2011
From: NYRT, RICHTER GEDEON
To: PAL KOCSIS; TARNAWA, ISTVAN; THAN MARTA; TIHANYI, KAROLY
Reel/Frame 026955/0085 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2006
From: KOCSIS, PAL; TARNAWA, ISTVAN; THAN, MARTA; TIHANYL, KAROLY; NEMETH, GYORGY
To: RICHTER GEDEON VEGYESZETI GYAR RT.
Reel/Frame 018348/0050 →
Priority Claims (1)
HU 0304095 · Dec 19, 2003 · national
Continuity (1)
Related Publication 20070129370A1 · Jun 7, 2007